Prognostic impact of p53 and/or NY-ESO-1 autoantibody induction in patients with gastroenterological cancers
- 1 May 2020
- journal article
- Published by Wiley
Abstract
No abstract availableKeywords
Funding Information
- JSPS KAKENHI Grants-in-Aid for Scientific Research (JP16K10520, JP15K10117)
This publication has 14 references indexed in Scilit:
- Prognostic significance of high serum p53 antibody titers in patients with esophageal squamous cell carcinomaEsophagus, 2018
- p53 molecular approach to diagnosis and treatment of esophageal squamous cell carcinomaAnnals of Gastroenterological Surgery, 2018
- Mutant p53 as a target for cancer treatmentEuropean Journal Of Cancer, 2017
- UALCAN: A Portal for Facilitating Tumor Subgroup Gene Expression and Survival AnalysesNeoplasia, 2017
- Panel of autoantibodies against multiple tumor‐associated antigens for detecting gastric cancerCancer Science, 2017
- Systematic review of time trends in the prevalence of Helicobacter pylori infection in China and the USAGut Pathogens, 2016
- NY-ESO-1 autoantibody as a tumor-specific biomarker for esophageal cancer: screening in 1969 patients with various cancersThe Esophagus, 2015
- Improvement of protein immobilization for the elaboration of tumor-associated antigen microarrays: Application to the sensitive and specific detection of tumor markers from breast cancer seraBiosensors and Bioelectronics, 2013
- Detection of anti-CUEC-23 antibodies in serum of patients with esophageal squamous cell carcinoma: a possible new serum marker for esophageal cancerThe Esophagus, 2009
- Titration of serum p53 antibodies in 1085 patients with various types of malignant tumorsCancer, 2003